From the Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA.
Cancer J. 2021;27(6):465-475. doi: 10.1097/PPO.0000000000000554.
Despite representing only 5% of all annual cancer diagnoses in the United States, pancreatic cancer is projected to become the second leading cause of cancer-related death within the next 10 years. Progress in the treatment of advanced pancreatic cancer has been slow. Systemic therapies rely on combination cytotoxic agents, with limited options at progression. Recently, poly(ADP-ribose) polymerase inhibitors have demonstrated clinical activity in patients with advanced pancreatic cancer and pathogenic variants in BRCA1, BRCA2, and PALB2. In this review, we discuss the development of poly(ADP-ribose) polymerase inhibitors in pancreatic cancer, relevant clinical trials, and future directions.
尽管在美国所有年度癌症诊断中仅占 5%，但预计在未来 10 年内，胰腺癌将成为第二大致癌相关死亡原因。晚期胰腺癌的治疗进展缓慢。系统疗法依赖于联合细胞毒性药物，在进展时选择有限。最近，聚（ADP-核糖）聚合酶抑制剂在携带 BRCA1、BRCA2 和 PALB2 种系变异的晚期胰腺癌患者中显示出临床活性。在这篇综述中，我们讨论了聚（ADP-核糖）聚合酶抑制剂在胰腺癌中的开发、相关临床试验和未来方向。
